AF
SMMT icon

Allworth Financial’s Summit Therapeutics SMMT Stock Holding History

Allworth Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51K Sell
172
-98
-36% -$1.74K ﹤0.01% 4419
2026
Q1 		$5.12K Buy
270
+201
+291% +$3.25K ﹤0.01% 3947
2025
Q4 		$1.21K Sell
69
-288
-81% -$5.42K ﹤0.01% 4308
2025
Q3 		$7.38K Sell
357
-123
-26% -$2.98K ﹤0.01% 3325
2025
Q2 		$10.2K Buy
480
+12
+3% +$274 ﹤0.01% 2886
2025
Q1 		$17.2K Buy
468
+98
+26% +$1.97K ﹤0.01% 2171
2024
Q4 		$8.7K Sell
370
-652
-64% -$12.6K ﹤0.01% 2491
2024
Q3 		$22.4K Buy
1,022
+1,000
+4,545% +$14K ﹤0.01% 1837
2024
Q2 		$194 Buy
+22
New +$119 ﹤0.01% 3555
2023
Q4 		– Sell
-64
Closed -$120 – 3607
2023
Q3 		$120 Buy
+64
New +$122 ﹤0.01% 3317

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Allworth Financial's SMMT Position: Q2 2026 in Review

Allworth Financial reduced its Summit Therapeutics (SMMT) stake by 36% in Q2 2026, selling an estimated $1.74K and leaving 172 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4419.

Allworth Financial first reported a position in SMMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $22.4K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Allworth Financial held 172 shares of Summit Therapeutics worth $2.51K as of Q2 2026.
  • Allworth Financial sold 98 Summit Therapeutics shares in Q2 2026, an estimated $1.74K.
  • Summit Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4419 holding.
  • Allworth Financial first reported a position in Summit Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • Allworth Financial's Summit Therapeutics position peaked at $22.4K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.